In this single-group , open-label , phase 2 study , 125 patients with indolent non-Hodgkin 's lymphomas who had not had a response to rituximab and an alkylating agent or had had a relapse within 6 months after receipt of those therapies were administered idelalisib , 150 mg twice daily , until the disease progressed or the patient withdrew from the study .